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were recorded and their relationship to VRC was determined. There
were two patients with mild elevation in liver function tests not
necessitating discontinuation of VRCwith spontaneous normalization
of liver function tests while on VRC. There was one patient with
confusion, noted three days after the initiation of VRC while on
narcotics. The confusion resolved upon discontinuing VRC and
adjusting narcotics. VRC was not restarted due to resolution of
fever and engraftment. Unlike prior reports we did not observe any
skin rashes or visual disturbances. Our experience conﬁrms the
safety and tolerability of VRC in HSCT patients.
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OPEN-LABEL, RANDOMIZED COMPARISON OF DOLASETRON VERSUS
ONDANSETRON FOR PREVENTION OF NAUSEA AND VOMITING DUR-
ING HIGH-DOSE CHEMOTHERAPY AND STEM CELL TRANSPLANTATION
Mandanas, R.A.1, Beveridge, R.A.2, Rifkin, R.M.3, Wallace, H.J.4,
Greenspan, A.5, Spitzer, G.6, Guo, H.7, Asmar, L.7 1. Cancer Care
Associates, Oklahoma City, OK; 2. Fairfax-Northern Virginia Hema-
tology-Oncology, Fairfax, VA; 3. Rocky Mountain Cancer Centers, Den-
ver, CO; 4. Piedmont Hematology-Oncology Associates, Winston-Salem,
NC; 5. Central Indiana Cancer Centers, Indianapolis, IN; 6. Cancer
Centers of the Carolinas, Greenville, SC; 7. US Oncology, Houston, TX
5-HT3 antagonists are now the standard for the prevention of
nausea and vomiting during conventional dose highly emetogenic
chemotherapy. Little data are available for the routine use of these
agents in the high-dose chemotherapy (HDC) and transplant set-
tings. Between May 1997 and March 2001, 197 patients were
randomized to received either Dolasetron (D) at 100 mg IV and
100 mg PO 8-12 hours later or Ondansetron (O) at 32 mg IV and
8 mg PO 8-12 hours later during HDC regimens for breast cancer
(STAMP V, n  96, 48.7%), non-Hodgkin’s lymphoma (BEAC,
n  83, 42.1%), and Hodgkin’s disease (CBV, n  18, 9.1%). In
addition to the 5-HT3 antagonist all patients also received dexa-
methasone 10 mg IV daily and an antiemetic pump containing
benadryl, lorazepam and dexamethasone (BAD) delivered at a con-
tinuous rate with patient-controlled on-demand bolus doses as
needed. Results: 164 (83 in D, 81 in O) of 197 patients were
evaluable after completing a daily diary which also included a visual
assessment scoring (VAS) for degree of nausea. Complete response
(no vomiting episode and no use of rescue medications) occurred in
D  36.1% and O  39.5%; major response (1 or 2 episodes of
vomiting with no rescue medications) in D  26.5% and O 
25.9%; and treatment failure (2 or more episodes in a 24 hour
period not relieved by BAD boluses or use of or request for rescue
medications) in D  23% and O  22%; all comparisons not
showing any signiﬁcant differences (p  0.5910). More than 70%
of patients in each arm showed varying degrees of nausea by VAS
scale. Subgroup analyses also failed to show any statistical differ-
ence in responses and failures between D and O when used for any
particular HDC regimen studied. Conclusion: D and O at the
doses studied are equivalent in responses and failures for the
prevention of nausea and vomiting in HDC and stem cell trans-
plantation. More than 70% of patients at least achieve good control
of vomiting with these agents in combination with dexamethasone
and an antiemetic (BAD) infusion pump.
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ROLE OF MUSIC THERAPY-BASED RELAXATION VS. EXPRESSIVE READ-
ING INTERVENTIONS IN BLOOD MARROW STEM CELL TRANSPLANTA-
TION
Liesveld, J.L.1, Sahler, O.J.Z.1, Hunter, B.C.2, Huang, L.-S.1, Oliva,
R.1 1. University of Rochester, Rochester, NY; 2. Nazareth College,
Rochester, NY
Patients undergoing hematopoietic stem cell transplantation of-
ten experience signiﬁcant pain, nausea, or emesis despite prophy-
lactic and therapeutic pharmacologic interventions. A randomized
controlled pilot study at the University of Rochester has been
conducted to determine the effects of a music therapy-based re-
laxation/stress reduction intervention, compared to an active con-
trol condition (expressive reading), on side effects related to
chemo-or radiotherapy and to determine whether any positive or
negative effects on graft or immune reconstitution were inﬂuenced
by these interventions. A total of 96 patients were accrued to the
study; 32 received music therapy, 33 expressive reading, and 31 no
intervention beyond usual supportive care. There were no signif-
icant differences in demographic or baseline variables among the
groups. The music therapy group received an average of 5.59
intervention seessions (range 1-11) and the expresive reading
group 6.06 (1-17) (NS) during their inpatient stays. Neither the
intervention nor the number of intervention sessions received
affected average number of days to engraftment or days to dis-
charge. However, both the music therapy and expressive reading
interventions resulted in a signiﬁcant reduction in pain and nausea
based on a visual analog scale administered before and after each
session. On Day 7 of transplant, those patients receiving music
therapy had a decrease in patient-requested medication as com-
pared to controls (1.22 vs. 4.27), but there was no signiﬁcant
difference between intervention groups in p.r.n. analgesic admin-
istration. No signiﬁcant difference among groups was found for
frequency of emesis. The relaxation intervention given was not
associated with differences in the levels of selected cytokines (IL-
1a, TNF-a, or interleukin-6) or in absolute lymphocyte counts at
Day 100. This pilot study demonstrates the feasibiltiy of relax-
ation interventions in a stem cell transplant population and begins
to discern possible areas of impact. Further controlled studies are
required to determine (1) whether any speciﬁc effects accrue to
music therapy interventions as compared with other relaxation
interventions, and (2) the role of time and attention, regardless of
speciﬁc activity, on immediate symptom relief.
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DETECTION AND VIRAL LOAD MONITORING OF BK VIRUS IN HEMOR-
RHAGIC CYSTITIS COMPLICATING BONE MARROW TRANSPLANT PA-
TIENTS
Manna, P.1, Wall, D.2, Grimely, M.2, Arnoldi, S.1, Vats, A.3 1.
ViraCor Laboratories, Lee’s Summit, MO; 2. Texas Transplant Insti-
tute/Southwest Texas Methodist Children’s Hospital, San Antonio, TX;
3. Children’s Hospital of Pittsburgh, Pittsburgh, PA
Introduction: Hemorrhagic cystitis causes signiﬁcant morbidity
and mortality in bone marrow transplant (BMT) patients. Recent
reports suggest the association of BK virus (BKV) in BMT patients
with hemorrhagic cystitis due to reactivation of BKV under im-
munosuppressive conditions. Thus, management of serious BKV
Table.
Number of patients 31
Mean age (range) 48 (25-65)
Sex Male 24 (77%), Female 7 (23%)
Underlying disease AML 11 (36%), NHL 7 (22%),
HD 4 (13%), MM 4 (13%), ALL
3 (10%), CML 1 (3%), Germ
cell 1 (3%)
Type of HSCT Auto 28 (90%), Allo 3 (10%)
Mean days of neutropeina
(range)
19 (7-57)
Route of VRC administration PO 15 (49%), IV 10 (32%),
IVPO 6 (19%)
Dose of VRC 400mg q12hr for two doses
then 200mg q 12hr
Mean days of VRC
administration (range)
13 (2-45)
Adverse effects Elevation of LFT’s 2 (6%),
Confusion 1 (3%)
HSCT, hemopoietc stem cell transplant; VRC, voriconazole; AMI,
acute myeloid leukemia; CML, chronic myeloid leukemia;
ALL, acute lymphoid leukemia; MM, multiple myeloma; HD,




infections in these patients requires early diagnosis, differentiation
from other conditions, and the ability to monitor the infection
after treatment. We have developed a real time quantitative PCR
assay for BKV and hereby present data to support its’ clinical
utility. Methods: The forward and reverse primers for our PCR
assay were designed to amplify a conserved region of Agno and
VP-1 genes. Additionally, to monitor the PCR product during the
ampliﬁcation, we designed a TaqMan probe that is complimentary
to the internal region of the ampliﬁed product. The assay has
undergone clinical validation and proﬁciency testing. We tested
our assay on 259 clinical specimens (129 blood, 124 urine, 3 ﬂuid,
1 tissue sample) from 62 BMT patients with hemorrhagic cystitis
for BKV load determination. Results: BKV was detected in 41
patients of the total 62 patients tested. Of the 129 blood samples,
68 tested positive for BKV, the result range is 400-1.9107copies/
ml. Similarly, of the 124 urine samples, 100 tested positive, the
result range is 100-109copies/ml. One BKV-positive patient fol-
lowed serially for hemorrhagic cystitis had persistently high levels
of BK virus in the urine (1.2-1.3109copies/ml) despite clearing
from the blood (with an initial viral load of 1.4106copies/ml).
This 15-year old male with unrelated donor marrow transplant for
treatment of paroxysmal nocturnal hemoglobinuria, had a stormy
post transplant course complicated by severe hemmorhagic cystitis,
aGVHD, and aspergillus and pseudomonas sinusitis. At 140 days
post transplant, he developed pancytopenia and sinopulmonary
disease with a mild ﬂair of hemmorhagic cystitis. No CMV, EBV
or adenovirus could be detected in this patient. However, on
further testing, BKV was found in bone marrow (6.5104 copies/
ml), tracheal aspirate (6.1104 copies/ml), and lung tissue (16
copies/cell) supporting progressive dissemination of the BK virus.
Conclusions: This assay can provide a sensitive, speciﬁc, reliable
and rapid method for diagnosis of life-threatening BKV infection
in BMT patients and would be useful in guiding as well as moni-
toring the response to speciﬁc therapy.
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EMPIRICAL STUDIES ON MOLECULAR FUNGAL DIAGNOSTICS
Manna, P.1, Arnoldi, S.1, Skopec, J.1, Schulenburg, E.1, Umbscheid,
T.1, Caulﬁeld, S.1, Vats, A.2 1. ViraCor Laboratories, Lee’s Summit,
MO; 2. Children’s Hospital of Pittsburgh, Pittsburgh, PA
Introduction: Fungal infections cause signiﬁcant morbidity and
mortality in bone marrow transplants. Despite medical advances, it
is estimated that up to 30% of cases of fungal infections may
remain undiagnosed and untreated at death. Thus, management of
serious fungal infections in these patients requires early diagnosis,
differentiation from other conditions and the ability to monitor the
infection after treatment. Unfortunately, rapid, accurate, sensitive,
and quantitative diagnostics for fungal infections do not exist at this
time. We investigated if quantitative real time PCR technology can
be applied to fungal infections to produce a diagnostic test that can
provide sensitive, accurate, and early detection. Methods: For
fungal genomic DNA isolation, we evaluated 3 commercially avail-
able kits: QIAamp Tissue Kit (Qiagen Inc), MagNA Pure Kit
(Roche Diagnostics), and E. Z. N. A. Fungal DNA Kit (Omega
Bio-tek). We selected 15 different published primer sets and ap-
plied them to both traditional and real time PCR. These primers
were reportedly designed for pan-fungal (PF), pan-Aspergillus (PA)
and pan-Candida (PC) categories. This assay was studied to eval-
uate ampliﬁcation of various Candida (n  4), Aspergillus sp (n  5)
and yeast DNA, both in pure form, in spiked blood, and in a
clinical urine sample. Results: Of the 3 commercially available kits
we evaluated for fungal genomic DNA isolation, our results
showed that the MagNA Pure Kit works better than other kits.
Eleven of the 15 published primer sets could detect fungal ge-
nomes by traditional PCR assay or by the real time assay using
non-speciﬁc SYBR Green dye. Four primer sets (1 PA, 1 PC, 2 PF)
failed to amplify several key fungal strains. Besides, we also iden-
tiﬁed cross ampliﬁcation by several PA and PC primers sets (i.e. PA
primer sets ampliﬁed Candida genomes and vice versa). Conclu-
sion: Developing a single molecular diagnostic assay that can
detect thousands of fungal species is a major challenge. In order to
develop such an assay, we ﬁrst evaluated the published primers.
Our results showed that the majority of them cross-react with
different fungal genera, while several failed to amplify key fungal
genomes—thus giving rise to both false positive and false negative
results. Currently, we are further investigating the development of
fungal assays based on TaqMan and LUX (Light Upon eXtension)
chemistry that would be rapid, sensitive, speciﬁc, and accurate.
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CLINICAL ROLE OF QUANTITATIVE VIRAL LOAD MONITORING FOR
ADENOVIRUS IN IMMUNOCOMPROMISED PATIENTS
Manna, P.1, Vats, A.2, Arnoldi, S.1, Skopec, J.1, Brewer, J.3, Flomen-
berg, P.4 1. ViraCor Laboratories, Kansas City, MO; 2. Children’s
Hospital of Pittsburgh, Pittsburgh, PA; 3. St Luke’s Hospital, Kansas
City, MO; 4. Thomas Jefferson University, Philadelphia, PA
Introduction: Adenovirus (AdV) can cause signiﬁcant morbidity
and mortality in BMT patients. Management of serious AdV in-
fections in these patients requires early diagnosis, differentiation
from other conditions, and the ability to monitor the infection
after treatment. We have developed a quantitative PCR assay for
AdV and hereby present data to support its clinical utility. Meth-
ods: We utilized the real time PCR technique (TaqMan) to quan-
tify AdV DNA in clinical specimens based on the conserved region
of the hexon gene. Additionally, we designed a minor groove-
binding (MGB) label to allow the use of a small oligonucleotide
probe to detect several AdV serotypes. Results: The assay detected
13 of 13 different AdV serotypes. We screened 154 clinical spec-
imens and identiﬁed 5 positive patients. Four positive patients were
monitored serially. Pt #1, with acute GVHD, following bone
marrow transplantation presented with fever, diarrhea and pro-
gressive liver dysfunction. The blood PCR for AdV was positive
and the viral load increased as the liver function worsened (from
5103 copies/ml with AST of 81 to 11103 copies/ml with AST of
198 and progressing to 1.9106 copies/ml with AST of 1061). The
patient died following the peak AdV load of 1.4108copies/ml.
The patient’s liver biopsy by EM found to have particles suggestive
of AdV. Pt #2, with chronic GVHD, on immunosuppressive ther-
apy presented with an acute febrile illness and was found to have an
initial blood AdV load of 5104 copies/ml. He promptly improved
after treatment with high dose IV IgG, with the viral load dropping
to 200 copies/ml. A few weeks later, after a 2nd increase in viral
load (6,200 copies/ml), he was again treated with IV IgG followed
by a decrease in viral load to 200 copies/ml. Four weeks later, after
another dose of IV IgG, the AdV load became undetectable. Pt#3
developed AdV load up to 1.6106copies/ml, did not respond to
IV IgG, but responded promptly to cidofovir with rapid drop in
AdV load and clinical improvement. Unfortunately, Pt#4 with low
AdV load 2103 copies/ml, treated with IV IgG without any
response, then rapidly developed hepatitis and died with very high
AdV load. Conclusions: Use of MGB probe allowed the detection
of multiple AdV serotypes with limited sequence homology. This
assay can provide a rapid method for diagnosis of life-threatening
AdV infection in BMT patients and would be useful in guiding as
well as monitoring the response to speciﬁc therapy.
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VIDEO VISUALIZATION OF THE SMALL BOWEL AIDS IN THE EVALUA-
TION OF INTESTINAL GRAFT VERSUS HOST DISEASE (GVHD)
Morris, J.D., Klooster, M., Condon, D., Zupan, C., Runge, S., Morris,
C.L. Loma Linda University Medical Center, Loma Linda, CA
Endoscopic evaluation for gastrointestinal graft versus host dis-
ease (GvHD) following allogeneic bone marrow transplant (BMT)
is of limited value for detection of distal small bowel disease. Video
visualization was used to evaluate the distal small bowel of a 9 year
old with severe gastrointestinal GvHD following a matched sibling
donor allogeneic BMT. The patient developed severe intestinal
GvHD 30 days after BMT characterized by secretory diarrhea
(1500 cc stool/day) nausea and vomiting. Endoscopy showed ul-
cerations of the duodenum and colon, and biopsies showed histo-
logical ﬁndings of GvHD. The patient was treated with tacrolimus,
methylprednisolone, and ATG. Stool output decreased to 500cc/
day after 3 weeks, but the nausea and abdominal pain persisted.
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